Since TNBC is ER/PR- and HER2-negative, common drugs used for breast cancer therapies such as tamoxifen; letrozole, which targets hormone receptors; and trastuzumab, which aims to destroy HER2 overexpression in breast cancer cells, are inapplicable in TNBC treatment. Here, ESR1 is linked to breast cancer.